

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/617,489 Filing Date TRANSMITTAL July 10, 2003 First Named Inventor FORM Thomas L. CANTOR Art Unit 1641 (to be used for all correspondence after initial filing) **Examiner Name** C. Cheu Attorney Docket Number 532212000623 11 Total Number of Pages in This Submission

ENCLOSURES (Check all that apply)						
Fee Transmit	tal Form	Drawing(s)		After Allowance Communication to TC		
Fee Attached		Licensing-related Papers		Appeal Communication to Board of Appeals and Interferences		
Amendment/f	Reply	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)		
After Fi	inal	Petition to Convert to a Provisional Application		Proprietary Information		
Affidavits/declaration(s)		Power of Attorney, Revocation Change of Correspondence		Status Letter		
Extension of Time Request		Terminal Disclaimer		Other Enclosure(s) (please Identify below):		
Express Abandonment Request		Request for Refund		PTO/SB/08a/b (4 pages plus duplicate)		
Information Disclosure Statement (2 pages)		CD, Number of CD(s)		References (93) Return Receipt Postcard		
Certified Cop		Landscape Table on	CD			
		Remarks				
Reply to Missing Parts under 37 CFR 1.52 or 1.53		cus	STOMER	NO.: 25225		
	SIGNATI	JRE OF APPLICANT, ATTOR	RNEY, OR	AGENT		
irm Name	MORRISON & FOEI	RSTER LLP				
Signature	w					
Printed name F	Peng Chen					
Date A	August 20, 2007		Reg. No.	43,543		
X (2 pages) Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Remarks CUS USE OF APPLICANT, ATTOR	STOMER	AGENT		

Express Mail, Airbill No. EM 057522035 US,	y paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Servi on the date shown below in an envelope addressed to: MS Issue Fee, Commissioner for Paten	ce as
P.O. Box 1450, Alexandria, VA 22313-1450		
Dated: August 20, 2007	Signature: (Lenay Rogus)	

AUG 9 0 2007

August 20, 2007

Signature:

August 20, 2007

Signature:

Patent Docket No. 532212000623

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Thomas L. CANTOR

Serial No.: 10/617,489

Filing Date: July 10, 2003

For: METHODS, KITS AND ANTIBODIES

FOR DETECTING PARATHYROID

HORMONE

Examiner: C. Cheu

Group Art Unit: 1641

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

MS Issue Fee Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

The documents set forth on the enclosed Form PTO/SB/08a/b have not been submitted or cited in the present application. It is understood that the Office is under no obligation to consider these documents at this time; however, to complete the record they are submitted. Copies of the non-patent literature documents are enclosed.

Document numbers 33 and 125 are from the prosecution of Applicants' related application number 10/945,608. Document numbers 34-36 are from the prosecution of Applicants' application number 10/799,476. Document numbers 66 and 67 were cited in application number 10/799,476. Document numbers 37-50 are from the prosecution of Applicants' application number 10/265,276. Document numbers 68-77 were cited in application number 10/265,276. Document

numbers 51-61 are from the prosecution of Applicants' application number 10/674,294. Document numbers 62-64 are from the prosecution of Applicants' application number 10/958,541. Document numbers 78-94 were cited in application number 10/958,541. Document number 65 is from the prosecution of Applicants' application number 11/516,912. Document numbers 95-124 were cited in application number 11/516,912.

Applicants believe that the documents are in no way destructive of patentability of the allowed claims. However, in the interest of completeness, they are submitted herewith.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent and Trademark Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. § 1.17 (p)) is required, Applicants petition for any required relief including extensions of time and authorize the Commissioner to charge the cost of such petition and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 532212000623.

Dated: August حدل , 2007

Respectfully submitted,

Peng Chen

By

Registration No.: 43,543 MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100 San Diego, California 92130-2040

(858) 720-5117



Complete if Known Substitute for form 1449/PTO 10/617,489 Application Number July 10, 2003 INFORMATION DISCLOSURE Filing Date Thomas L. CANTOR First Named Inventor STATEMENT BY APPLICANT 1641 Art Unit C. Cheu (Use as many sheets as necessary) Examiner Name 532212000623 4 Attorney Docket Number 1 of Sheet

			<u> </u>	TENT DOCUMENTS	Pages, Columns, Lines, Where
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	1.	US-4,086,196	04/1978	Tregear	
	2.	US-4,851,356	07/1989	Canfield et al.	
	3.	US-4,968,669	11/1990	Rosenblatt et al.	
	4.	US-5,026,653	06/1991	Lee et al.	
	5.	US-5,075,218	12/1991	Jette et al.	
	6.	US-5,093,233	03/1992	Rosenblatt et al.	
	7.	US-5,208,041	05/1993	Sindrey	
	8.	US-5,256,543	10/1993	Pouletty et al.	
	9.	US-5,317,010	05/1994	Pang et al.	
	10.	US-5,382,658	01/1995	Kronis et al.	
	11.	US-5,434,246	07/1995	Fukuda et al.	
	12.	US-5,496,801	03/1996	Holthuis et al.	
	13.	US-5,589,452	12/1996	Krstenansky et al.	
	14.	US-5,639,617	06/1997	Bohuon	
"	15.	US-5,695,955	12/1997	Krstenansky et al.	
	16.	US-5,723,577	03/1998	Dong	
	17.	US-5,747,456	05/1998	Chorev et al.	
	18.	US-5,783,558	07/1998	Duvos et al.	
	19.	US-5,798,225	08/1998	Krstenansky et al.	
	20.	US-5,807,823	09/1998	Krstenansky et al.	
	21.	US-5,840,831	11/1998	Hamachi et al.	
	22.	US-5,955,264	09/1999	Seed et al.	
	23.	US-5,958,384	09/1999	Holick et al.	
	24.	US-6,124,314	09/2000	Cameron et al.	
	25.	US-6,387,711	05/2002	Sundaram et al.	
	26.	US-6,689,566	02/2004	Cantor et al.	
	27.	US-2003/0171288	09/2003	Andrew et al.	
	28.	US-2004/0067526	04/2004	Cantor	
	29.	US-2005/0069952	03/2005	Cantor et al.	
	30.	US-2005/0170443	08/2005	Cantor	
	31.	US-2005/0202506	09/2005	Cantor	
	32.	US-2007/0098726	05/2007	Cantor et al.	

<u> </u>		FOREIC	ON PATENT	OCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code³-Number⁴-Kind Code⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

<u></u>	
Examiner	Date
Signature	Considered

				Complete if Known		
Sut	Substitute for form 1449/PTO			Application Number	10/617,489	
16	JEORMATIO	אר שכ	CLOSURE	Filing Date	July 10, 2003	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Named Inventor	Thomas L. CANTOR	
0) I W I CIAICIA	ואוטו	LIONI	Art Unit	1641	
	(Use as many	sheets as ne	ecessary)	Examiner Name	C. Cheu	
Sheet	2	of	4	Attorney Docket Number	532212000623	

*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\)Applicant's unique citation designation number (optional). \(^2\)See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\)Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \(^6\)Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	33.	Advisory Action from 10/945,608, mailed on July 23, 2007	Ĺ
	34.	Restriction Requirement from 10/799,476, mailed on January 10, 2007	
	35.	Response to Restriction Requirement from 10/799,476, filed on January 24, 2007	
	36.	Non-Final Office Action from 10/799,476, mailed on April 17, 2007	
	37.	Restriction Requirement from 10/265,276, mailed on August 20, 2004	
	38.	Response to Restriction Requirement from 10/265,276, filed on December 18, 2004	
	39.	Non-Final Office Action from 10/265,276, mailed on January 24, 2005	
	40.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on April 25, 2005	
	41.	Non-Final Office Action from 10/265,276, mailed on June 28, 2005	
	42.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on October 7, 2005	
	43.	Final Rejection from 10/265,276, mailed on January 4, 2006	
	44.	Amendment After Final Action (37 CFR Section 1.116) from 10/265,276, filed on April 4, 2006	
	45.	Advisory Action from 10/265,276, mailed on May 18, 2006	
	46.	Pre-Appeal Brief Request for Review from 10/265,276, filed on June 13, 2006	
	47.	Notice of Panel Decision from Pre-Appeal Brief Review from 10/265,276, mailed on August 4, 2006	
	48.	Non-Final Office Action from 10/265,276, mailed on October 20, 2006	
	49.	Amendment in Response to Non-Final Office Action from 10/265,276, filed on January 19, 2007	
	50.	Final Rejection from 10/265,276, mailed on April 19, 2007	
	51.	Restriction Requirement from 10/674,294, mailed on June 2, 2006	
	52.	Response to Restriction Requirement from 10/674,294, filed on June 28, 2006	
	53.	Non-Final Office Action from 10/674,294, mailed on September 11, 2006	
	54.	Amendment in Response to Non-Final Office Action from 10/674,294, filed on December 13, 2006	
	55.	Final Rejection from 10/674,294, mailed on February 15, 2007	
	56.	Amendment After Final Action Under 37 CFR 1.116 from 10/674,294, filed on April 13, 2007	
	57.	Advisory Action from 10/674,294, mailed on April 27, 2007	
	58.	Examiner Interview Summary from 10/674,294, mailed on May 17, 2007	
	59.	Amendment After Final Action Under 37 CFR 1.116 from 10/674,294, filed on May 18, 2007	
	60.	Substance of Examiner Interview from 10/674,294, filed on June 14, 2007	
	61.	Non-Final Office Action from 10/674,294, mailed on June 18, 2007	
	62.	Restriction Requirement from 10/958,541, mailed on March 7, 2007	

Examiner	Date	
Signature	Consider	ed

Complete if Known Substitute for form 1449/PTO 10/617,489 Application Number July 10, 2003 INFORMATION DISCLOSURE Filing Date Thomas L. CANTOR First Named Inventor STATEMENT BY APPLICANT Art Unit 1641 (Use as many sheets as necessary) C. Cheu Examiner Name 532212000623 4 Attorney Docket Number Sheet 3 of

	63.	Response to Restriction Requirement from 10/958,541, filed on April 4, 2007	
	64.	Non-Final Office Action from 10/958,541, mailed on August 3, 2007	
	65.	Restriction Requirement from 11/516,912, mailed on July 31, 2007	
	66.	CANFIELD et al., Endocrinology (1982) 110(5):1555-1563	
	67.	MOTTE et al., Journal of Immunology (1987) 138(10):3332-3338	
	68.	KURIYAMA et al., Blood Purification (1998) 16:43-48	
	69.	MONIER-FAUGERE et al., Journal of the American Society of Nephrology (1999) 11:1093-1099	
	70.	NISSENSON et al., J. Biol. Chem. (1988) 263(26):12866-12871	
	71.	PARTHEMORE et al., J. Clin. Endocrinol. Metab. (1978) 47(2):284-289	
	72.	PODBESEK et al., Endocrinology (1983) 112:1000-1006	
	73.	RICHARDS et al., Clin. Nephrol. (1999) 51(2):126-127	
	74.	STAFFORD-JOHNSON et al., J. Comput. Assist. Tomogr. (1998) 22(2):295-299	
	75.	STEWART et al., J. Clin. Invest. (1988) 81(2):596-600	
	76.	THOMPSON et al., PNAS USA (1988) 85(15):5673-5677	
	77.	YATES et al., J. Clin. Invest. (1988) 81(3):932-938	
	78.	BHASKARAN and PONNUSWAMY, Int. J. Pept. Protein Res. (1988) 32:242-255	
	79.	D'AMOUR et al., Endocrinology (1985) 117:127-134	
	80.	D'AMOUR et al., J. Immunoassay (1989) 10:191-205	
	81.	DELEAGE and ROUX, Protein Engineering (1987) 1:289-294	
	82.	GHILLANI et al., Cancer Res. (1989) 49(23):6845-6851	
	83.	HENIKOFF et al., PNAS USA (1992) 89:10915-10919	
	84.	HOPP and WOODS, PNAS USA (1981) 78:3824-3828	
	85.	JANIN, Nature (1979) 277:491-492	
	86.	KYTE and DOOLITTLE, J. Mol. Biol. (1982) 157:105-132	
	87.	LEI et al., J. Biol. Chem. (1995) 270(20):1182-1186	
	88.	LOVERIDGE et al., Endocrinology (1991) 128(4):1938-1946	
-	89.	MERRIFIELD et al., Biochemistry (1982) 21:5020	
ļ	90.	NIALL et al., PNAS USA (1969) 64:771-778	
<u> </u>	91.	RABBANI et al., J. Biol. Chem. (1984) 259:2949-2955	\top
<u> </u>	92.	STEVENS et al., Journal of Immunological Methods (1988) 108:271-278	
	93.	STRYER, (ed.), Biochemistry 2 nd ed., (1981) pp. 13-16	
	94.	JANEWAY et al., Immunobiology, 5 th ed., Appendix I, pages 624-625	
	95.	BERSON et al., J. Clin. Invest. (1956) 35:170-190	
<u> </u>	96.	BERSON et al., PNAS USA (1963) 49:613-617	\top
	97.	BROADUS et al., J. Clin. Invest. (1977) 60:771-783	
	98.	BROSSARD et al., J. Bone and Miner. Res. (1999) 14:S444	
	99.	CANTERBURY et al., J. Clin. Invest. (1975) 55:1245-1253	
	100.	DAMBACHER et al., Clinical Science (1979) 57:435-443	
—	101.	ENDRES et al., Kidney International (1982) 21:132	
	102.	FLUECK et al., Proceedings of the 58th American Meeting of the Endocrine Society, June 1976	
	103.	FREITAG et al., New England Journal of Medicine (1978) 298:29-32	
	1.00.		

Examiner	Date	
Signature	Considered	

		_		Complete if Known		
Sub	Substitute for form 1449/PTO			Application Number	10/617,489	
10	JEORMATIO!	א סוכ	CLOSURE	Filing Date	July 10, 2003	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			First Named Inventor	Thomas L. CANTOR	
3			AFFEIOAI4I	Art Unit	1641	
	(Use as many sheets as necessary)			Examiner Name	C. Cheu	
Sheet	4	of	4	Attorney Docket Number	532212000623	

104.	GALLAGHER et al., J. Lab. Clin. Med. (1980) 95:373-385	
105.	HABENER and POTTS, New England Journal of Medicine (1978) 299:580-585, 635-644	
106.	KAO et al., Clin. Chem. (1982) 28:69-74	
107.		
108.	LAFFERTY, Medicine (1966) 45:247-260	
109.	MALLETTE et al., J. Clin. Endocrinology Metab. (1982) 54:1017-1024	
110.		
111.		
112.		
113.	RODBARD and HUTT, "Statistical Analysis of Radioimmunoassays and Immunoradiometric (labeled antibody) Assays" in Assays, Radioimmunoassays and Related Procedures in Medicine, Vol. 1, Vienna: International Atomic Energy Agency, Vienna, (1974) pp. 165-192	
114.	RODBARD et al., J. Clin. Endocrinology Metab. (1968) 28:1412-1418	
115.	ROOS et al., J. Clin. Endocrinology and Metab. (1981) 53:709-721	
116.	SEGRE et al., American Journal of Medicine (1974) 56:774-784	
117.	SEGRE et al., Biochemistry (1977) 16:2417-2427	
118.	SEGRE et al., J. Clin. Invest. (1981) 67:439-448	
119.	SEGRE et al., J. Clin. Invest. (1981) 67:449-457	
120.	SEGRE et al., J. Clin. Invest. (1972) 51:3163-3172	
121.	SILVERMAN and YALOW, J. Clin. Invest. (1973) 52:1958-1971	
122.	SLATOPOLSKY et al., Journal of American Society of Nephrology (1999) 10:625A	
123.	TRAVIS, (ed.), "Clinical Radioimmunoassay" in State-of-the-Art Scientific Newsletter, Inc., Anaheim, CA 92803, (1980) pp.13-16	
124.		
	105. 106. 107. 108. 109. 110. 111. 112. 113. 114. 115. 116. 117. 118. 119. 120. 121.	 105. HABENER and POTTS, New England Journal of Medicine (1978) 299:580-585, 635-644 106. KAO et al., Clin. Chem. (1982) 28:69-74 107. KEUTMANN et al., Biochemistry (1978) 17:5723-5729 108. LAFFERTY, Medicine (1966) 45:247-260 109. MALLETTE et al., J. Clin. Endocrinology Metab. (1982) 54:1017-1024 110. MALLETTE, Ligand Review (1979) 1:18-19 111. NUSSBAUM et al., Clin. Chem. (1988) 33(3):1364-1367 112. RAISZ et al., Annals International Medicine (1979) 91:739-740 113. RODBARD and HUTT, "Statistical Analysis of Radioimmunoassays and Immunoradiometric (labeled antibody) Assays" in Assays, Radioimmunoassays and Related Procedures in Medicine, Vol. 1, Vienna: International Atomic Energy Agency, Vienna, (1974) pp. 165-192 114. RODBARD et al., J. Clin. Endocrinology Metab. (1968) 28:1412-1418 115. ROOS et al., J. Clin. Endocrinology and Metab. (1981) 53:709-721 116. SEGRE et al., American Journal of Medicine (1974) 56:774-784 117. SEGRE et al., Biochemistry (1977) 16:2417-2427 118. SEGRE et al., J. Clin. Invest. (1981) 67:439-448 119. SEGRE et al., J. Clin. Invest. (1981) 67:449-457 120. SEGRE et al., J. Clin. Invest. (1973) 52:1958-1971 121. SILVERMAN and YALOW, J. Clin. Invest. (1973) 52:1958-1971 122. SLATOPOLSKY et al., Journal of American Society of Nephrology (1999) 10:625A 123. TRAVIS, (ed.), "Clinical Radioimmunoassay" in State-of-the-Art Scientific Newsletter, Inc., Anaheim, CA 92803, (1980) pp. 13-16 124. WOOD et al., J. Clin. Chem. Biochemistry (1980) 18:789-795

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Date	
Examiner Date	
Signature Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.